Preclinical development of molecular-targeted agents for cancer

Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.

(2010) HJ Burstein et al.   CANCER RESEARCH

Do We Have to Change the Way Targeted Drugs Are Developed?

(2010) Alberto Ocana et al.   JOURNAL OF CLINICAL ONCOLOGY

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin

(2009) T. Hay et al.   CANCER RESEARCH

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer

(2009) Alberto Ocana et al.   CURRENT DRUG TARGETS

Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study

(2009) Ian Chau et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice

(2009) Tracy E. Strecker et al.   JNCI-Journal of the National Cancer Institute

In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells

(2009) Erina Vlashi et al.   JNCI-Journal of the National Cancer Institute

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

(2009) M Garayoa et al.   LEUKEMIA

Genes that mediate breast cancer metastasis to the brain

(2009) Paula D. Bos et al.   NATURE

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthetic Lethality — A New Direction in Cancer-Drug Development

(2009) J. Dirk Iglehart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

(2009) Elizabeth Iorns et al.   PLoS One

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

(2008) E. M. Ocio et al.   BLOOD

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo

(2008) C. S. Mitsiades et al.   CANCER RESEARCH

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

(2008) Nicholas C Turner et al.   EMBO JOURNAL

Translational research: are we on the right track?

(2008) Charles L. Sawyers   JOURNAL OF CLINICAL INVESTIGATION

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate

(2008) Daniel P. Bradley et al.   MAGNETIC RESONANCE IMAGING

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

(2008) H Korkaya et al.   ONCOGENE

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

(2008) Qing-Bai She et al.   PLoS One

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc 716 mice

(2008) T. Fujishita et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

(2008) A. Dubrovska et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Co-evolution of tumor cells and their microenvironment

(2008) Kornelia Polyak et al.   TRENDS IN GENETICS